long-acting muscarinic M3 antagonists (AstraZeneca)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Namelong-acting muscarinic M3 antagonists (AstraZeneca)
Drug Alias Namelong-acting muscarinic M3 antagonists (Argenta)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMuscarinic acetylcholine receptor M3 antagonists
TargetsMuscarinic acetylcholine receptor M3
Therapy Area/IndicationsPulmonary Disease, Chronic Obstructive
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesArgenta Discovery
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesArgenta DiscoveryAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsPulmonary Disease, Chronic Obstructive

Other Information

ATC CodeN/A
Related LinksN/A